What is ORIC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ORIC?

P/E (TTM) is n/a and 52-week range is $7.23 to $14.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ORIC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ORIC?

The company profile lists net income (TTM) near $-140M, EPS (TTM) near $-1.35 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Oric Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 103.5M shares outstanding, ISIN US68622P1093 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Oric Pharmaceuticals Inc

$ORIC

Health Care · Biotechnology

IR Run Scenarios

$11.99

-0.33%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 104 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.

Employees

104

Website

oricpharma.com/

IPO

2020-04-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)